https://www.selleckchem.com/pr....oducts/crt0066101-di
We determined to investigate the incidence and clinical impact of new cerebral microbleeds after intravenous thrombolysis in patients with acute stroke. The THAWS was a multicenter, randomized trial to study the efficacy and safety of intravenous thrombolysis with alteplase in patients with wake-up stroke or unknown onset stroke. Prescheduled T2*-weighted imaging assessed cerebral microbleeds at three time points baseline, 22-36 h, and 7-14 days. Outcomes included new cerebral microbleeds development, modified Rankin
Like
Comment
Share
